A scientist whose research has been at the center of controversy over an Alzheimer’s drug candidate has been charged with fraud. Dr. Wang’s studies underpinned research into a diagnostic test for Alzheimer’s disease and simufilam, a drug in advanced clinical trials. Simufilam’s manufacturer, Cassava Sciences, a pharmaceutical company based in Texas, has said the drug improves cognition in Alzheimer’s patients. Alzheimer’s disease affects roughly six million Americans — a number that is expected to double by 2050 — and promising treatments generate tremendous excitement. Cassava’s stock soared after each round of reported results from its trials.

---

Persons: Hoau, Yan Wang, — Organizations: City College of New, National Institutes of Health, Sciences Locations: City College of New York, Texas